Polen Capital Management LLC Has $551.02 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Polen Capital Management LLC lessened its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,405,748 shares of the company’s stock after selling 448,911 shares during the quarter. Novo Nordisk A/S makes up about 1.5% of Polen Capital Management LLC’s investment portfolio, making the stock its 22nd largest position. Polen Capital Management LLC owned 0.14% of Novo Nordisk A/S worth $551,022,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of the company. Norman Fields Gottscho Capital Management LLC boosted its stake in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock valued at $5,482,000 after buying an additional 19,870 shares in the last quarter. Bryn Mawr Capital Management LLC boosted its stake in Novo Nordisk A/S by 358.8% in the 4th quarter. Bryn Mawr Capital Management LLC now owns 38,898 shares of the company’s stock valued at $3,346,000 after buying an additional 30,420 shares in the last quarter. Versant Capital Management Inc acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $86,000. Talbot Financial LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $4,066,000. Finally, Clear Creek Financial Management LLC acquired a new stake in Novo Nordisk A/S in the 4th quarter valued at $450,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts recently commented on the company. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, BMO Capital Markets reduced their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Three research analysts have rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $145.25.

Novo Nordisk A/S Trading Up 1.8 %

NVO stock opened at $77.22 on Monday. The company has a market cap of $346.54 billion, a P/E ratio of 23.47, a PEG ratio of 0.90 and a beta of 0.42. Novo Nordisk A/S has a twelve month low of $73.80 and a twelve month high of $148.15. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62. The business has a fifty day moving average of $83.95 and a 200-day moving average of $102.79.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, equities research analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be issued a $0.7874 dividend. This represents a yield of 1.2%. The ex-dividend date is Monday, March 31st. This is an increase from Novo Nordisk A/S’s previous semi-annual dividend of $0.51. Novo Nordisk A/S’s dividend payout ratio is currently 47.72%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.